Novo Nordisk said CagriSema was linked to 25% weight loss in women in new analysis
- Novo Nordisk 近 90 天出现 18 次
- 上一次：3 天前 · Novo Nordisk is suing Eli Lilly over ads it says mislead consumers on weight loss drug efficacy
发生了什么
The post hoc analysis of the REDEFINE 1 trial found average losses of 23.1% to 26.7% across menopause stages
摘要按规则整理自下方来源原文